Atopic Dermatitis

EADV 2025: New phase 3 data reveal delgocitinib cream's efficacy for chronic hand eczema in adolescents, confirming its safety profile in adults.

EADV 2025: Data will highlight the PDE4 inhibitor's efficacy across diverse populations and 3 common skin conditions: seborrheic dermatitis, atopic dermatitis, and psoriasis.

MRGPRX2 antagonism is the only known mechanism of action designed to modulate mast cells and sensory neurons, both key drivers of lesions and itch in AD.

Discover the latest advancements in atopic dermatitis treatment, including new topical agents and biologics, enhancing care for patients with moderate to severe conditions.

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

Your daily dose of the clinical news you may have missed.

In response to the prompt, "Generate a photo of a person with [skin condition]," 3 of 4 generative AI models significantly underrepresented diverse skin tones.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

GX-03 has proven effective in preclinical trials, reducing disease severity by more than 50% vs placebo. Data from the current study are expected by year end.

Tralokinumab met key trial endpoints with no new safety signals in treatment of moderate-to-severe hand eczema, in adults who are candidates for systemic therapy.

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

The investigational IL-13 inhibitor showed topline EASI-75 of 66.9% and reduced injection frequency in part A of the APEX phase 2 clinical trial.

Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.

Atopic dermatitis is not just "another rash on the schedule. It could be the reason that patient doesn't leave the house," Shahriari says.

In the phase 2b trial, the IL-2 pathway agonist and Treg proliferator demonstrated a strong dose-dependent biological response across 3 treatment arms vs placebo.

RAD 2025: Multidisciplinary collaboration at disease-specific meetings drives clinical and therapeutic progress in AD, Dr Yu told Patient Care.

Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.

At RAD 2025, Dr Yu shared hopes for more real-world data and targeted treatment approaches for chronic hand eczema.

RAD 2025: Yale dermatologist Mona Shahriari, MD, urged primary care clinicians to refer patients with AD who don't improve to prevent cumulative emotional burden.

RAD 2025: Expert insights on the psychosocial burden of AD, flexible dosing, and cross-specialty collaboration in pediatric care.

RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.

RAD 2025: Brad Glick, DO, MPH, discusses the intensity of TSW symptoms and cautions against assuming there is mental health disturbance at work.